| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 44.6 | 189.5 | 102.2 |
| Other income | 1.7 | -0.4 | 1.6 |
| Total income | 46.3 | 189.0 | 103.8 |
| Profit before exceptional items & tax | 0.5 | 1.3 | 1.7 |
| Profit before tax | 0.5 | 1.3 | 1.7 |
| Net profit | 1.0 | 1.0 | 1.4 |
| Operating margin | 1.1% | 0.7% | 1.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -28.60% |
|---|---|
| Net profit, quarter on quarter | +0.00% |
| Revenue, year on year | -56.40% |
| Operating profit, year on year | -1300.00% |
| Operating profit, quarter on quarter | -170.60% |
BSE results filing, NSE: AAREYDRUGS. Figures extracted from the filing.
Aarey Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹107.48
- Market cap
- ₹304.8 Cr
- Revenue (annual)
- ₹472.3 Cr
- Net profit (annual)
- ₹3.97 Cr
- P/E (TTM)
- 73.0×Sector 47.4×
- Promoter holding
- 42.79%+5.08% QoQ
- FII holding
- 4.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aarey Drugs & Pharmaceuticals Ltd
All →Aarey Drugs & Pharmaceuticals Other Announcement
Aarey Drugs & Pharmaceuticals Ltd filed its quarterly shareholding pattern. This is a routine regulatory compliance disclosure regarding the company's equity distribution.
Aarey Drugs & Pharmaceuticals Annual General Meeting
Aarey Drugs approved the Board Report and called its 36th Annual General Meeting to be held on September 30, 2026.
Aarey Drugs & Pharmaceuticals Board Meeting Date
Aarey Drugs & Pharmaceuticals will hold a board meeting on August 14, 2026, to consider and approve the standalone unaudited financial results for the June 2026 quarter.
Aarey Drugs & Pharmaceuticals Capital Structure Change
Aarey Drugs allotted 25.20 lakh equity shares upon conversion of warrants, raising Rs. 12.06 Crore. This issuance changes the company's paid-up equity capital.
- Value
- ₹12.06 Cr
Aarey Drugs & Pharmaceuticals Other Announcement
The company has filed its quarterly shareholding pattern for the period ending June 30, 2026, as per regulatory requirements.
Aarey Drugs & Pharmaceuticals Other Announcement
Aarey Drugs & Pharmaceuticals filed its Annual Secretarial Compliance Report for FY 2025-26. The report details regulatory compliance status and observations from the practicing company secretary.